CD8A and neoplasm: The ex vivo analysis revealed significant differences between the control and therapy group at follow-up; tumors in the therapy group had significantly higher percentage of apoptotic cells (TUNEL: 17.1 ± 5.6% versus 52.3 ± 17.2%; p = 0.001), higher number of TILs (CD8+: 71.9 ± 55.6 versus 395.4 ± 522.5; p = 0.049) and significantly lower tumor cell proliferation (Ki-67: 58.7 ± 8.6% versus 27.2 ± 9.7%; p = 0.001) than the control group.